The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.[4][5]
Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.[6][5]
Medical usesedit
In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.[4]
In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.[5]
Referencesedit
^"Peginterferon beta-1a (Plegridy) Use During Pregnancy". Drugs.com. 22 July 2019. Retrieved 25 June 2020.
^"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^"Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
^ abcde"Plegridy EPAR". European Medicines Agency (EMA). Retrieved 24 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^"Drug Approval Package: Plegridy (peginterferon beta-1a) prefilled syringe and Plegridy Pen (peginterferon beta-1a) prefilled pen NDA #125499". U.S. Food and Drug Administration (FDA). 17 September 2014. Retrieved 25 June 2020.
peginterferon, beta, sold, under, brand, name, plegridy, medication, used, treat, multiple, sclerosis, clinical, datatrade, namesplegridy, plegridy, penother, namesbiib, 017ahfs, drugs, commonographmedlineplusa614059license, dataus, dailymed, pregnancycategory. Peginterferon beta 1a sold under the brand name Plegridy is medication used to treat multiple sclerosis 4 5 Peginterferon beta 1aClinical dataTrade namesPlegridy Plegridy PenOther namesBIIB 017AHFS Drugs comMonographMedlinePlusa614059License dataUS DailyMed Peginterferon beta 1aPregnancycategoryAU D 1 Routes ofadministrationSubcutaneous injectionDrug classAntineoplastic agentATC codeL03AB13 WHO Legal statusLegal statusAU S4 Prescription only 2 CA only 3 US only 4 EU Rx only 5 In general Prescription only IdentifiersIUPAC name 1 Ether with N 3 hydroxy 2 methylpropyl interferon b 1a human a methyl w hydroxy poly oxy 1 2 ethanediyl CAS Number1211327 92 2DrugBankDB09122UNIII8309403R0KEGGD10483Chemical and physical dataFormulaC913H1417N246O256PS7 C2H4O nMolar mass44000 g mol 1The most common side effects include headache muscle pain joint pain influenza flu like symptoms pyrexia fever chills asthenia weakness and erythema reddening of the skin pain or pruritus itching at the injection site 4 5 Peginterferon beta 1a was approved for medical use in the United States and in the European Union in 2014 6 5 Medical uses editIn the United States peginterferon beta 1a is indicated for the treatment of relapsing forms of multiple sclerosis to include clinically isolated syndrome relapsing remitting disease and active secondary progressive disease in adults 4 In the European Union peginterferon beta 1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults 5 References edit Peginterferon beta 1a Plegridy Use During Pregnancy Drugs com 22 July 2019 Retrieved 25 June 2020 Prescription medicines registration of new chemical entities in Australia 2014 Therapeutic Goods Administration TGA 21 June 2022 Retrieved 10 April 2023 Health Canada New Drug Authorizations 2015 Highlights Health Canada 4 May 2016 Retrieved 7 April 2024 a b c d Plegridy peginterferon beta 1a kit Plegridy Pen peginterferon beta 1a kit Plegridy peginterferon beta 1a injection solution DailyMed 30 March 2020 Retrieved 25 June 2020 a b c d e Plegridy EPAR European Medicines Agency EMA Retrieved 24 June 2020 Text was copied from this source which is copyright European Medicines Agency Reproduction is authorized provided the source is acknowledged Drug Approval Package Plegridy peginterferon beta 1a prefilled syringe and Plegridy Pen peginterferon beta 1a prefilled pen NDA 125499 U S Food and Drug Administration FDA 17 September 2014 Retrieved 25 June 2020 External links editPlegridy at the U S National Library of Medicine Medical Subject Headings MeSH Portal nbsp Medicine nbsp This antineoplastic or immunomodulatory drug article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Peginterferon beta 1a amp oldid 1218179160, wikipedia, wiki, book, books, library,
